Drugs / Clinical / Drug / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Accent Therapeutics / Aimovig / Alex Azar / Amgen / ARCH Venture Partners / ASCO / aTyr Pharma / Beam Therapeutics / Blueprint Medicines / Bob Nelsen / Broad Institute / CAR-T / Celgene / Celsius Therapeutics / deals / Drug Pricing / EIP Pharma / Eli Lilly / erenumab / Eric Lander / FDA / Fentanyl / FogPharma / Greg Verdine / Illumina / IQVIA Holdings / James Watson / Jounce Therapeutics / Kymriah / Life Sciences / Loxo Oncology / Lucemyra / MeiraGTx / Migraines / Nektar Therapeutics / Novartis / Pfizer / President Trump / Roundups / Sesen Bio / Syndax Pharmaceuticals

Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout

Posted on: May 18, 2018   |   Posted by: Biotech Mag

Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout

There's nothing abstract about a 20 percent jump in a company's stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society...

Continue reading ...